A study of patients receiving T-DXd (Trastuzumab Deruxtecan) for treatment of HER2+ unresectable and/or metastatic breast cancer

Trial Identifier:	D9673R00025
Sponsor:	AstraZeneca
NCTID::	NCT05592483
Start Date:	March 2023
Primary Completion Date:	December 2025
Study Completion Date:	December 2025
Condition:	Breast Cancer

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Stay informed about new Trial Results Summaries with our email notification service

Trial Locations

No locations posted.

Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is 3 More London Riverside, London SE1 2AQ.